JP7328891B2 - 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 - Google Patents

融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 Download PDF

Info

Publication number
JP7328891B2
JP7328891B2 JP2019524255A JP2019524255A JP7328891B2 JP 7328891 B2 JP7328891 B2 JP 7328891B2 JP 2019524255 A JP2019524255 A JP 2019524255A JP 2019524255 A JP2019524255 A JP 2019524255A JP 7328891 B2 JP7328891 B2 JP 7328891B2
Authority
JP
Japan
Prior art keywords
protein
fgf21
pharmaceutical composition
terminus
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019524255A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502053A (ja
Inventor
ホン・ハンナ
キム・ジュンファン
チェ・ヒョンホ
キム・ドフン
キム・テワン
オ・セウン
ソン・ムヨン
キム・ジョンギュン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of JP2020502053A publication Critical patent/JP2020502053A/ja
Priority to JP2022156834A priority Critical patent/JP2023002571A/ja
Application granted granted Critical
Publication of JP7328891B2 publication Critical patent/JP7328891B2/ja
Priority to JP2025072400A priority patent/JP2025114622A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019524255A 2016-11-10 2017-11-10 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物 Active JP7328891B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022156834A JP2023002571A (ja) 2016-11-10 2022-09-29 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物
JP2025072400A JP2025114622A (ja) 2016-11-10 2025-04-24 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160149866 2016-11-10
KR10-2016-0149866 2016-11-10
PCT/KR2017/012726 WO2018088838A1 (en) 2016-11-10 2017-11-10 Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022156834A Division JP2023002571A (ja) 2016-11-10 2022-09-29 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物

Publications (2)

Publication Number Publication Date
JP2020502053A JP2020502053A (ja) 2020-01-23
JP7328891B2 true JP7328891B2 (ja) 2023-08-17

Family

ID=62110477

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019524255A Active JP7328891B2 (ja) 2016-11-10 2017-11-10 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物
JP2022156834A Pending JP2023002571A (ja) 2016-11-10 2022-09-29 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物
JP2025072400A Pending JP2025114622A (ja) 2016-11-10 2025-04-24 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022156834A Pending JP2023002571A (ja) 2016-11-10 2022-09-29 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物
JP2025072400A Pending JP2025114622A (ja) 2016-11-10 2025-04-24 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物

Country Status (15)

Country Link
US (1) US11179440B2 (https=)
EP (1) EP3568149B1 (https=)
JP (3) JP7328891B2 (https=)
KR (1) KR102692516B1 (https=)
CN (1) CN110121355B (https=)
AU (2) AU2017358289C1 (https=)
BR (1) BR112019009581A2 (https=)
CA (1) CA3042512A1 (https=)
ES (1) ES3023833T3 (https=)
HU (1) HUE071618T2 (https=)
MX (1) MX2019005380A (https=)
NZ (2) NZ794312A (https=)
PL (1) PL3568149T3 (https=)
WO (1) WO2018088838A1 (https=)
ZA (1) ZA201903306B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102668200B1 (ko) * 2015-10-28 2024-05-23 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
CN110709520B (zh) 2017-04-21 2024-04-05 株式会社柳韩洋行 用于产生双功能蛋白质及其衍生物的方法
CN112566655B (zh) 2018-06-21 2025-11-07 赛诺菲 具有优化的活性比率的fgf21化合物/glp-1r激动剂组合
CN111662373B (zh) 2019-03-05 2024-05-14 广东东阳光药业股份有限公司 一种多肽分子及其应用
US20220288169A1 (en) * 2019-05-24 2022-09-15 The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College Compositions and methods for the treatment and prevention of hypoglycemic complications
CN115322794B (zh) 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
WO2022002408A1 (en) * 2020-07-02 2022-01-06 Sanofi Glp-1r agonist / fgf21 fusion proteins
CA3224743A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
CN113956344A (zh) * 2021-10-14 2022-01-21 江南大学 一种新型治疗肝癌的fgf类似物及其应用
WO2025058417A1 (ko) * 2023-09-11 2025-03-20 서울대학교병원 안지오포이에틴-1 융합 단백질 및 이의 용도
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018534929A (ja) 2015-10-28 2018-11-29 ユーハン・コーポレイションＹＵＨＡＮ Ｃｏｒｐｏｒａｔｉｏｎ 長時間作用型ｆｇｆ２１融合タンパク質およびそれを含む医薬組成物
JP2019500013A (ja) 2015-10-28 2019-01-10 ユーハン・コーポレイションＹＵＨＡＮ Ｃｏｒｐｏｒａｔｉｏｎ デュアル機能タンパク質およびそれを含む医薬組成物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0387173A (ja) 1987-09-10 1991-04-11 Teijin Ltd ヒト活性化天然型ファクター８ｃの製造方法及びそれに用いる形質転換体
WO1990002175A1 (en) 1988-08-16 1990-03-08 Novo Nordisk A/S A method of producing polypeptides by culturing eukaryotic cells in the presence of protease inhibitors
US5851800A (en) 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
MXPA05013565A (es) 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
CA2557782A1 (en) 2004-03-17 2005-10-06 Eli Lilly And Company Glycol linked fgf-21 compounds
JP2006094727A (ja) * 2004-09-28 2006-04-13 Masaki Kamakura 細胞増殖促進作用及び器官再生促進作用を有すポリペプチドをコードする遺伝子
LT2126106T (lt) 2007-02-23 2018-01-10 Sk Chemicals Co., Ltd. Viii faktoriaus ir jo darinių gavimo ir gryninimo būdas
CA2693504A1 (en) 2007-08-03 2009-02-12 Eli Lilly And Company Treatment for obesity
EP2296690B1 (en) * 2008-06-04 2016-11-30 Amgen, Inc Fgf21 mutants and uses thereof
CN101732715B (zh) * 2008-11-07 2012-02-15 中国人民解放军军事医学科学院放射与辐射医学研究所 LSECtin及其融合蛋白在制备抑制癌细胞向肝转移药物中的应用
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
EP2427207B1 (en) * 2009-05-05 2017-08-16 Amgen, Inc Fgf21 mutants and uses thereof
HRP20240135T1 (hr) 2009-05-05 2024-04-12 Amgen Inc. Fgf21 mutanti i njihove upotrebe
EP2440235A1 (en) 2009-06-11 2012-04-18 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
CN101993485B (zh) * 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
ES2543634T3 (es) 2010-01-22 2015-08-20 Novo Nordisk A/S Proceso para preparación de FGF-21 con grado de O-glicosilación bajo
EP2595647A1 (en) 2010-07-20 2013-05-29 Novo Nordisk A/S N-terminal modified fgf21 compounds
CN102370686B (zh) * 2010-08-26 2013-09-18 上海中医药大学附属曙光医院 治疗慢性肝病的药物组合物及其应用
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
US9574002B2 (en) 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
MX2014002260A (es) 2011-08-31 2014-08-18 Amgen Inc Factor de crecimiento de fibroblasto 21 para usar en el tratamiento de diabetes tipo 1.
TW201315742A (zh) * 2011-09-26 2013-04-16 Novartis Ag 治療代謝病症之雙功能蛋白質
CN102558358A (zh) * 2011-12-30 2012-07-11 张海涛 人成纤维细胞生长因子21融合蛋白及其突变体的制备与应用
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
TWI513705B (zh) * 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
CN103860565B (zh) * 2012-12-10 2017-05-17 中国人民解放军军事医学科学院毒物药物研究所 一种治疗肝纤维化的药物组合物
US9550820B2 (en) 2013-02-22 2017-01-24 New York University Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use
CN105792851B (zh) 2013-09-13 2023-10-10 斯克利普斯研究所 修饰的治疗剂及其组合物
WO2016048995A2 (en) * 2014-09-23 2016-03-31 Salk Institute For Biological Studies Fgf19 truncations and mutants and uses thereof
SMT202100388T1 (it) * 2014-10-24 2021-09-14 Bristol Myers Squibb Co Polipeptidi fgf-21 modificati e loro usi
KR20160088656A (ko) * 2015-01-16 2016-07-26 주식회사유한양행 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물
CN105288592A (zh) 2015-11-02 2016-02-03 哈尔滨博翱生物医药技术开发有限公司 成纤维细胞生长因子-21成熟肽在制备肝纤维化治疗药物中的应用
EP4470551A3 (en) * 2017-03-14 2025-02-26 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
CN110709520B (zh) 2017-04-21 2024-04-05 株式会社柳韩洋行 用于产生双功能蛋白质及其衍生物的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018534929A (ja) 2015-10-28 2018-11-29 ユーハン・コーポレイションＹＵＨＡＮ Ｃｏｒｐｏｒａｔｉｏｎ 長時間作用型ｆｇｆ２１融合タンパク質およびそれを含む医薬組成物
JP2019500013A (ja) 2015-10-28 2019-01-10 ユーハン・コーポレイションＹＵＨＡＮ Ｃｏｒｐｏｒａｔｉｏｎ デュアル機能タンパク質およびそれを含む医薬組成物

Also Published As

Publication number Publication date
EP3568149C0 (en) 2025-03-12
ES3023833T3 (en) 2025-06-03
EP3568149A4 (en) 2020-07-22
WO2018088838A1 (en) 2018-05-17
KR102692516B1 (ko) 2024-08-08
JP2025114622A (ja) 2025-08-05
EP3568149B1 (en) 2025-03-12
US20190314452A1 (en) 2019-10-17
AU2017358289A1 (en) 2019-06-20
NZ794312A (en) 2026-01-30
RU2019117767A3 (https=) 2021-01-28
CN110121355B (zh) 2023-09-12
RU2019117767A (ru) 2020-12-10
NZ752661A (en) 2025-10-31
AU2017358289C1 (en) 2025-05-08
AU2017358289B2 (en) 2024-12-19
JP2020502053A (ja) 2020-01-23
HUE071618T2 (hu) 2025-09-28
BR112019009581A2 (pt) 2019-10-08
PL3568149T3 (pl) 2025-07-07
NZ794313A (en) 2026-01-30
CA3042512A1 (en) 2018-05-17
CN110121355A (zh) 2019-08-13
EP3568149A1 (en) 2019-11-20
JP2023002571A (ja) 2023-01-10
MX2019005380A (es) 2019-08-12
US11179440B2 (en) 2021-11-23
AU2025201790A1 (en) 2025-04-03
ZA201903306B (en) 2020-09-30
KR20180052545A (ko) 2018-05-18

Similar Documents

Publication Publication Date Title
JP7328891B2 (ja) 融合タンパク質を含む、肝炎、肝線維症、および肝硬変を予防または処置するための医薬組成物
KR102927838B1 (ko) 이중 작용 단백질 및 이를 포함하는 약학적 조성물
JP7453943B2 (ja) 長時間作用型ｆｇｆ２１融合タンパク質およびそれを含む医薬組成物
RU2795548C2 (ru) Фармацевтическая композиция для предотвращения или лечения гепатита, фиброза печени и цирроза печени, включающая слитые белки
HK40012348A (en) Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins
HK40012348B (zh) 用於预防或治疗肝炎、肝纤维化和肝硬化的包含融合蛋白的药物组合物
HK40091844A (zh) 双功能蛋白质和包含其的药物组合物
HK40086042A (zh) 双功能蛋白质和包含其的药物组合物
BR112018008805B1 (pt) Proteína de função dupla, composição farmacêutica e molécula de ácido nucleico isolada que compreendem a dita proteína, uso terapêutico da mesma e vetor de expressão
HK1257373B (en) Dual function proteins and pharmaceutical composition comprising same

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201013

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220309

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220929

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220929

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221011

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230320

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230522

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230606

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230705

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230804

R150 Certificate of patent or registration of utility model

Ref document number: 7328891

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150